“While we have been highly confident in the exceptional quality of our state-of-the-art face serum, CellProof, since its release last June, it is gratifying to receive such categorical validation of our product’s efficacy,” stated Asma Ishaq, CEO of Modere.

LOS ANGELES (PRWEB)
May 12, 2020

Modere (the “Company”), a healthy, safe and clean-lifestyle brand of dietary supplements, household, and personal care products with a presence worldwide, today announced the definitive results of two third-party clinical trials conducted on the company’s new collagen and hyaluronic acid-based face serum, CellProof ® Serum.

Measured at two and/or four weeks, the skin’s appearance measurably improved in all or nearly all test subjects across five test categories. At both two and four weeks, 100% of test subjects experienced increased skin hydration, and at two weeks 80% of users experienced improved skin tone. Over four weeks, skin texture and density improved in 85% of users, while exfoliation increased in 92% of test subjects. An additional clinical trial further validated CellProof® Serum’s effect on skin health – showing significant reduction in the appearance of wrinkles.

“While we have been highly confident in the exceptional quality of our state-of-the-art face serum, CellProof, since its release last June, it is gratifying to receive such categorical validation of our product’s efficacy,” stated Asma Ishaq, CEO of Modere.

Modere CellProof® Serum’s exclusive formula combines patented, cosmetic grade BioCell Collagen® CG with a potent botanical complex and Vitamin C to hydrate, firm, and visibly lift and illuminate the skin within minutes. The topical serum’s age-defying benefits are compounded when used in tandem with the company’s award-winning nutraceutical, Liquid BioCell®.

About Modere

Modere (http://www.modere.com) offers a category-leading portfolio of live clean lifestyle essentials including beauty and personal care, health and wellness, and household products that are equal parts high-performing and scientifically designed. We believe modern health involves pure nutrition and a clean environment across all our product categories. Modere brings a holistic, live clean approach to well-being, and our products reflect a commitment to excellence and innovation with tested formulas proven around the globe. The recipient of multiple third-party validations, our line includes products that are US EPA Safer Choice-approved, EWG Verified™, NSF Certified and gray-water appropriate. The company is a proud supporter of Vitamin Angels®.

Share article on social media or email:

One single, four-band filter set to detect nucleotides conjugated to FAM, HEX, ROX or C5. Optimized for use with LEDs with output in the spectral regions of 465-475nm, 520-535nm, 580-595nm & 635-645n.

“This has provided us with valuable experience and application expertise and puts us in a unique position to help in the effort to test as many individuals as possible,” says Newell Lessell, CEO of Chroma.

BELLOWS FALLS, Vt. (PRWEB)
May 12, 2020

To help countries around the world increase testing for the COVID-19 virus, Chroma Technology Corp. has moved to three-shift, seven-days-a-week production of desperately needed optical filters required for polymerase chain reaction (PCR) test systems.

Chroma Technology, a leading supplier of optical filters for the life sciences, medical diagnostics, and machine vision, has seen sharply increased demand from manufacturers of these qPCR and Digital PCR systems, which are used to determine if patients are infected with the coronavirus that causes COVID-19. In response, Chroma has placed its priority on the production of these filters, reshuffling manufacturing scheduling and capacity.

Chroma has been supplying high-quality, sputter-coated filters for PCR to major test equipment manufacturers for many years.

“This has provided us with valuable experience and application expertise and puts us in a unique position to help in the effort to test as many individuals as possible,” says Newell Lessell, CEO of Chroma. Being a 100% employee-owned company fosters increased engagement, especially when family and loved ones may be at risk.

“I couldn’t be more proud of the round-the-clock effort our manufacturing employees have put into PCR filter production. As one team member recently said so well, “This is something we can do to help and we’re proud to do it,’” added Lessell.

As an essential business, Chroma moved quickly in early March to reorganize operations to safeguard worker health while ensuring uninterrupted supply to customers. Ramping up on short notice to round-the-clock production presented a challenge, but Chroma’s employee owners were willing to do whatever was necessary to support this important work. Within a week, the company had turned the lights on and those lights are still burning.

Chroma’s ET Premium Sputtered filters for fluorescence applications, including their filters for PCR, provide unmatched levels of spectral precision. This allows for minimizing the spectral overlap which is always present between fluorescent probes and optimizing the filter pass bands. The high degree of spectral precision ensures reproducible, reliable results, allowing for six or more distinct fluorescence channels. Coupled with high out-of-band blocking (≥ OD6) and extremely steep transitions from high transmission to deep blocking, these filters deliver the highest available signal-to-noise ratios.

For more information about Chroma’s PCR filters, contact Chroma at sales@chroma.com or visit https://www.chroma.com/polymerase-chain-reaction.

About Chroma Technology

Founded in 1991 as a 100% employee-owned company and now a B Corporation, Chroma Technology is a leading manufacturer and OEM supplier of highly precise optical filters using thin-film coating technology. With a reputation built on dedicated customer service, including free technical and applications support, we remain committed to serving the scientific and technical communities in their pursuit of the scientific endeavor. Learn more at http://www.chroma.com.

Share article on social media or email:

The app is invaluable for communicating with OB patients, even more critical at this juncture in the COVID-19 pandemic. The ease that it provides for connecting with patients and augmenting digital practice is of vital importance, especially in these times.

WASHINGTON (PRWEB)
May 12, 2020

Babyscripts, the leading virtual care platform for managing obstetrics, has announced the release of Babyscripts myJourney, the next-generation version of its virtual care program for pregnancy that allows healthcare providers to seamlessly deliver a new model of prenatal and postpartum care. The new version delivers an upgraded modern interface for providers and patients, as well as expanded educational content to support mothers up to a year postpartum, while continuing to enable remote monitoring experiences for weight and blood pressure that allow providers to transition care seamlessly outside the clinic.

With the release of Babyscripts myJourney, the mobile app has enhanced its robust educational experience with the addition of new research-based content, which continues to be available to mothers in both English and Spanish. The latest version of the app enriches patient engagement and support through daily inspirations, tips, and reminders; while continuing to provide access to gestational age appropriate content, email campaigns, satisfaction surveys, and weight monitoring.

Current Babyscripts clients have used this custom campaign functionality with great success to disseminate information around COVID-19, with patient engagement rates nearing 100% for content from everything to practice policy changes and medical advice to local information like library and food bank closures that affect life outside of healthcare.

“The app is invaluable for communicating with OB patients, even more critical at this juncture in the COVID-19 pandemic,” said Dr. Mark Rosing, Chair of Obstetrics & Gynecology at SBH Health System in the Bronx. “Onboarding is simple, the user interface is welcoming and self-explanatory, and the ease that it provides for connecting with patients and augmenting digital practice is of vital importance, especially in these times.”

The Babyscripts experience is newly available to mothers up to a year postpartum, with 52 weeks of postpartum content now accessible through the app. This postpartum content is designed to help mothers take care of their new babies, monitoring for important milestones and navigating topics like infant sleep and nutrition, as well as helping mothers take care of themselves — a topic that is often overlooked by current standards of care.

The enhanced Babyscripts experience is delivered to the patient through an upgraded interface that is streamlined, modern, and easy to navigate; as well as completely customizable by the provider with their preferred colors, logo and content to help personalize the experience for each mother. The product will also be available for white-labelling.

“Delivering better care to the patient is at the heart of everything we do, whether that’s as simple as changing a font for a better reading experience or as high-level as adding new features,” said Juan Pablo Segura, President and co-founder of Babyscripts. “Patient and provider feedback has driven our innovation from day one, and we are confident that it’s helped us make Babyscripts myJourney the best product on the market for delivering better pregnancies.”

All current Babyscripts clients will migrate to Babyscripts myJourney over the course of the next six months.

Through the mobile app and remote monitoring experiences, Babyscripts myJourney enables earlier risk detection and intervention, driving improved outcomes and increasing patient engagement and satisfaction. With Babyscripts myJourney’s seamless integration, providers can automate certain aspects of care to streamline workflow, improve patient outcomes, and increase practice reimbursement.

About Babyscripts

Babyscripts is a company delivering a new model for prenatal and postpartum care that is transforming the way expectant mothers use technology to work with their healthcare providers. We’ve spent the last six years delivering the most-implemented mobile clinical solution for remote monitoring in pregnancy, with the mission to eliminate maternal mortality and improve access for all mothers. For more information on our virtual care solution and to request a demo, visit http://www.babyscripts.com.

Share article on social media or email:

Dr. Berman has spent his entire career dedicated to the recovery of patients with spinal issues and pain.

I know what you’re going through.

CORONA, Calif. (PRWEB)
May 12, 2020

It brings us great excitement to introduce Healthpointe’s newest Neurologist, Dr. Blake Berman. Dr. Berman is a board-certified neurosurgeon, who was ranked 1st nationally during his academic residency. His post-graduate training years focused on complex spine and neurologic trauma. He completed his undergraduate work at the University of LaVerne, his medical degree at the Western University of Health Sciences, and his neurosurgical fellowship at the Arrowhead Regional Medical Center and San Bernardino County Hospital. He completed his General Surgery Residency at Michigan State University/St. John Oakland General Hospital, and his Neurosurgical Residency at the Arrowhead Regional Medical Center/San Bernardino County Hospital.

Dr. Berman has a unique method when it comes to helping our spine patients, with his, “I know what you’re going through,” approach. In fact, Dr. Berman was a long-time spine patient himself. Extended stays in many hospital rooms brought him great awareness in understanding how doctors treat patients, and in neurology itself. Not only did this pique his interest in neurology, but it gave him experience into how patients with spinal issues truly feel. He knows the impact that these complications can have on someone’s life, as his own injuries caused his career to suffer. In light of this, he also knows what it’s like to get your life back after all of it, and he wants his patients to make that same recovery.

While Dr. Berman has an unmatched passion for his patients, his enthusiasm for his family and music is equally significant. Dr. Berman puts an emphasis on maintaining a work-life-family balance, in which he stresses the importance of maintaining healthy personal relationships, and continuing his pursuit and passion for his music. His family and personal values further benefit our patients, as he holds himself to highest ethical standards and principles. He knows that there can be some unscrupulous physicians in neurological surgeries, but his personal values are consistent with ethical medical practice, and at Healthpointe, he is not only able, but encouraged to abide by his ethics when it comes to patient care. It is through this practice that he is able to “maintain excellence by upholding high cultural, ethical, and professional standards,” and set the example for neurologic professionals. Furthermore, he wants his patients to know that he will be available to them through the entirety of their treatment while providing his best care, as he knows how difficult it is to be a patient with spinal issues.

Dr. Berman will be treating at the Temecula, Perris, Corona, Colton, Ontario offices.

For more information about Healthpointe’s spine surgery and neurology services and the many other services that we have available, please check out Healthpointe’s website. To make an appointment, please call (888) 824-5580 or click here to schedule.

Share article on social media or email:

“With help from Interdisp, we will be able to provide the best service and reliable support to our customers in Russia and Belarus,” said Vincent Wortel, EMEA sales manager, DuPont Nutrition & Biosciences.

WILMINGTON, Del. (PRWEB)
May 12, 2020

DuPont Nutrition & Biosciences (N&B) has announced the selection of Interdisp JCS as the new distribution partner for all personal care ingredients in Russia and Belarus. Beginning May 1, Interdisp JCS will represent both the DuPont GENENCARE®OSMS portfolio and DuPont preservative portfolio for personal care.

The GENENCARE®OSMS product line contains a range of all-natural, 100 percent plant-based active ingredients – derived from sugar beets – that deliver benefits across skin, hair care and color cosmetics. This product range includes: GENENCARE®OSMS BA, GENENCARE®OSMS CC, GENENCARE®OSMS MI and GENENCARE®OSMS PRO.

The DuPont preservative portfolio is comprised of classical and natural derived products under the trade name KATHON™CG and NEOLONE™. Interdisp JCS will be the go-to supplier of these product portfolios across the region.

DuPont has long worked with Interdisp JSC to distribute other applications in the region. Expansion of the partnership with Interdisp will allow DuPont to improve logistics and provide greater technical service levels to customers.

“With help from Interdisp, we will be able to provide the best service and reliable support to our customers in Russia and Belarus,” said Vincent Wortel, EMEA sales manager, DuPont Nutrition & Biosciences.

“We’re always working to optimize our network of channel partners in the region and are thrilled to be able to expand our successful partnership with Interdisp,” added Wortel.

About Interdisp

Interdisp company has been successfully operating in the market of Russia and the CIS countries since 1996, importing high-quality chemical products for the production of cosmetics and household chemicals from well-known manufacturers. Our highly qualified specialists will help you choose the best solution for your tasks. We can help with the development of recipes. http://www.interdisp-group.ru

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food and worker safety. More information can be found at http://www.dupont.com.

About DuPont Nutrition & Biosciences

DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: http://www.dupontnutritionandbiosciences.com or [http://www.biosciences.dupont.com.

# # #

05/12/2020

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

For further information contact:

Irma Tessensohn                    

+31-6-217-05-230                    

Irma.Tessensohn@dupont.com                    

Mrs. Tatiana Sitina

Head of Personal Care Department

+7 926 337 31 28

sitina@msk.interdisp.ru

Share article on social media or email:

Dr. Keith Chertok, Periodontist in Berkeley, CA, Invests in New Technology

Guided implant surgery offers more predictable, less invasive treatment and a more comfortable experience for patients overall.

BERKLEY, Calif. (PRWEB)
May 12, 2020

Dr. Keith Chertok improves treatment planning and the overall patient experience with a new, leading-edge intraoral scanner. A trusted periodontist in Berkeley, CA, Dr. Chertok recently invested in the 3Shape TRIOS 3 intraoral scanner. This state-of-the-art technology improves the precision of dental implant surgery along with increasing patient comfort during the diagnostic and planning phases. With this intraoral scanner, modern dental implants, and his periodontal expertise, Dr. Chertok and his team are able to offer patients a chance to restore their smiles in just one day with immediate load dental implants.

In the past, patients were required to receive messy, gag-inducing impressions. These were uncomfortable and left patients with a bad taste in their mouths. Now, with the TRIOS 3 by his side, Dr. Chertok can offer a modern, quick, and convenient alternative that captures a highly accurate digital impression instead.

This digital impression is taken using a small, wand-link device. After just seconds scanning the mouth, it can re-create the exact shape and look of both the teeth and gums. The digital, three-dimensional re-creation can be shown to patients on a screen in their treatment room to better understand their oral health, and their recommended treatment plan.

As a digital impression, these scans can be combined with cone beam CT imaging and TRIOS software for accurate and calculated dental implant planning. Digital planning and physical surgical guides eliminate the guesswork associated with dental implant surgery for single and full mouth dental implant cases. Considering bone density levels and nerve positions, guided surgery ensures implants are placed precisely as planned and in the ideal location for lasting stability.

As Dr. Chertok states, “Guided implant surgery offers more predictable, less invasive treatment and a more comfortable experience for patients overall.”

Dr. Chertok’s dental implant surgery planning also keeps the look of the final esthetic smile in mind from the beginning considering the shape and size of the new teeth as well as an even gum line. Facilitating more than just an esthetic smile, these intraoral scans also help make same-day dental implants possible.

Dr. Chertok can remove damaged or decayed teeth and strategically place a dental implant that is capable of holding a new tooth in just one appointment. After the implant is placed, a digital scan is taken using the TRIOS 3 intraoral scanner. This can be immediately sent to a specialized lab to make a temporary tooth in just one day.

To learn more about Dr. Chertok, his advanced technology, or his skilled staff, visit http://www.berkeleyperiodontist.com. To schedule a dental implant consultation and experience his new intraoral scanner in person, call 510-548-0150.

About the Periodontist

Dr. Keith Chertok offers specialized periodontal care and dental implants to the Berkeley, CA area and beyond. For the last 30 years, he’s offered minimally invasive techniques always implementing the most cutting-edge technology. He started his career graduating in the top five percent of his class from the New York University College of Dentistry before completing his specialty training in Periodontics and Implantology through University of California, San Francisco (UCSF). A leader in periodontics, he has taught at UCSF, the Dugoni School of Dentistry, and lectures across the country. For ten years he was also the attending periodontist in charge of periodontal education for new dental residents at the Veterans Hospital Healthcare System of Northern California at Mare Island. Among numerous other services, he offers single to full mouth dental implant transformations, revolutionary LANAP® laser gum disease treatment, and minimally invasive gum recession solutions. To learn more about Dr. Chertok or the services he and his specialized team offers, visit their website at http://www.berkeleyperiodontist.com or call 510-548-0150 to schedule a personalized consultation.

Share article on social media or email:

“As states reopen, people return to work, and health systems resume elective procedures, we’re here to help make those transitions as safe as possible.”

ATLANTA (PRWEB)
May 12, 2020

Jvion, a leading provider of clinical AI, today announced a new offering within its COVID Response Suite to help America return to work safely. The Employer Recovery Package is an employee safety assessment tool for businesses, health systems and government agencies on the path to reopening. The solution allows organizations to evaluate the health and safety of their employees for the duration of the pandemic and beyond, and develop informed back-to-work strategies to protect their most vulnerable workers.

“As states reopen, people return to work, and health systems resume elective procedures, we’re here to help make those transitions as safe as possible,” said Jvion CPO Dr. John Showalter, who led the development of the Employer Recovery solution. “Our mission has always been to prevent avoidable patient harm, and if patients get sick at work, that’s harm that could have been avoided with the right intervention. That’s why we applied everything we’ve learned in the last decade with our Jvion CORE to help employers protect their workforce and build trust with employees and customers.”

The centerpiece of the solution is an AI-honed assessment powered by the Jvion CORE™, an AI asset that contains de-identified claims data from 30 million patients as well as data on social determinants of health. Employees respond to questions informed by the latest COVID-19 symptoms identified by the CDC and questions determined to have high predictive value by the Jvion CORE. The assessment has been rigorously validated by data scientists and a panel of medical experts.

After assessing employees’ risk for infection and exposure, the CORE provides one of three dispositions: cleared to return, medical clearance required, or cannot return to work. Those requiring medical clearance can be directed to a telehealth consult. Although employers are notified whether employees are cleared to return, health details behind the back-to-work dispositions are shared with the employee only to protect their privacy. The Jvion CORE is also HIPAA compliant and HITRUST certified for information security to further ensure confidentiality.

Considering the uncertainty of how long the pandemic will last and the potential for surges complicated by the upcoming flu season, employers need to remain vigilant in monitoring the health and safety of their employees on an ongoing basis. This is critical to building trust with their employees as well as their customers or patients. The back-to-work assessment can be made available through state or employer portals and can be optimized by taking in employee sponsored claims data to provide proactive and ongoing monitoring of employee health risks. This enables employers to make proactive decisions about remote work assignments, campus closings, and personnel substitutions to protect vulnerable workers.

The Employer Recovery Package is the latest addition to the Jvion COVID Response Suite, a collection of resources Jvion has provided to enable a proactive response to COVID-19. This includes the COVID Community Vulnerability Map, a publicly available tool that identifies the communities most vulnerable to severe cases during an outbreak, along with the social determinants of health driving their risk. To date, the map has been viewed over two million times and informed proactive outreach efforts by medical students and other community groups to vulnerable patient populations. Now, as states begin to reopen, Jvion is applying intelligence from the COVID Response Suite to help employers bring workers back as safely as possible.

More than half of US states have moved to reopen parts of their economy, yet employers are still grappling with how to keep their workforce safe. Last week, Jvion announced that Augusta University Health System was the first to use Jvion’s back-to-work assessment for the employees of businesses in the greater Augusta community.

To learn more about the COVID Response Suite, visit jvion.com/jvionclinicalai.

About Jvion:

Jvion enables healthcare organizations to prevent avoidable patient harm and lower costs through its clinical AI solution. An industry first, the Jvion CORE goes beyond simple predictive analytics and machine learning to identify patients on a trajectory to becoming high risk and for whom intervention will likely be successful. Jvion determines the interventions that will more effectively reduce risk and enable clinical action. And it accelerates time to value by leveraging established patient-level intelligence to drive engagement across hospitals, populations, and patients. To date, the Jvion CORE has been deployed across about 50 hospital systems and 300 hospitals, who report average reductions of 30% for preventable harm incidents and annual cost savings of $6.3 million. For more information, visit http://www.jvion.com.

Jvion PR Contact:

Lexi Herosian

lexi@scratchmm.com

Share article on social media or email: